AbinscienceELISA其它型号产品
| Stability and Storage | The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition. |
| Detection method | Colorimetric |
| Sample type | Plasma, Serum |
| Assay type | Quantitative |
| Sensitivity | 0.156 μg/ml |
| Range | 0.31-5 μg/mL |
| Recovery | 80-120% |
| Background | Olokizumab (CDP6038), a humanized monoclonal antibody (mAb) specific for the interleukin-6 (IL-6) cytokine, is currently in development for the treatment of rheumatoid arthritis (RA). It targets the IL-6 cytokine rather than the receptor, and selectively blocks the final assembly of the signalling complex. In Phase I (healthy volunteers) and IIa (patients with RA on MTX) clinical trials, olokizumab was well tolerated after intravenous and subcutaneous delivery with a median plasma half-life of approximately 31 days, 76% bioavailability and no apparent antidrug antibody-mediated clearance. Olokizumab also markedly reduced free IL-6 levels and suppressed C-reactive protein (CRP) up to 12 weeks after single-dose subcutaneous administration in patients with RA. |
| Alternative Names | CDP 6038, CAS: 1007223-17-7 |
| Shipping | 2-8 ℃ |
| Specifications | Olokizumab |
| Note | For Research Use Only. |
| 长度(mm) | |
| 宽度(mm) | |
| 高度(mm) | |
| 重量(kg) |
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
询价
微信小程序
7X24小时在线咨询